Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
A sound methodological approach (PBPK-VBE modeling) applied to a regulatory question, but based on simulation and in vitro data without in vivo clinical confirmation across the lower dose range, making it supportive rather than definitive evidence.
This is an early-stage preclinical study in a xenograft model demonstrating proof-of-concept for a novel hydrogel delivery system, lacking human clinical data and reporting only surrogate tumor outcomes without survival numbers.